Check out your Company Bowl for anonymous work chats.
Today we gathered with our distributor partners from across Europe to talk about what really matters: getting better #ProstateCancer diagnostics into the hands of more clinicians to reach more patients who can't afford to wait. A huge thank you to every distributor who joined us. Your knowledge of local healthcare systems, your clinical relationships, and your commitment to patients are what turn innovation into impact. #AIinHealthcare #MedicalImaging
Detecting focal liver lesions early is essential, but in ultrasound, performance still largely depends on operator experience. One of the latest studies published in 𝐧𝐩𝐣 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 shows that a deep learning model that analyzes liver ultrasound videos in real time significantly improved lesion detection for both novice and experienced sonographers, especially in the case of small lesions measuring less than 10 mm, where early intervention is most critical. This highlights a broader challenge in medical imaging: many image-based assessments still rely heavily on operator-dependent interpretation, limiting reproducibility and scalability. This is the case for MRI-based quantification in diffuse liver disease, another common and clinically relevant liver condition. At Quibim, we aim to reduce this dependency by enabling more standardized and reproducible MRI-based measurements. Our AI tool, QP-Liver®, enables automated, quantitative assessment of liver fat and iron from abdominal MRI, providing objective, non-invasive measurements without the need for biopsy. Together, these advances point towards a more standardized and reproducible use of imaging, enabling earlier and more reliable assessment across different types of liver disease. 📄 https://lnkd.in/ehEstvUn #WorldLiverDay #LiverHealth #AIinMedicine #DigitalHealth #Radiology
🇨🇦 From April 16-19 we’re in the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Le Westin Montreal. This year’s theme — 𝘚𝘦𝘦𝘪𝘯𝘨 𝘞𝘩𝘢𝘵 𝘔𝘢𝘵𝘵𝘦𝘳𝘴: 𝘋𝘳𝘪𝘷𝘪𝘯𝘨 𝘊𝘢𝘯𝘢𝘥𝘪𝘢𝘯 𝘙𝘢𝘥𝘪𝘰𝘭𝘰𝘨𝘺 𝘍𝘰𝘳𝘸𝘢𝘳𝘥 — reflects exactly what we’re building at Quibim: improving cancer detection through AI-powered imaging biomarkers and advancing a fully connected prostate ecosystem, from acquisition to diagnosis. Visit us at Booth 12 to explore what’s next in radiology. Niles Geminiuc Joshua Moss Emmanuel Loubet Nathan Clark Edward Ramirez R.T. (R)(MR) B.S. ----- 🇨🇦 Du 16 au 19 avril, nous sommes présents au congrès scientifique annuel de l'Association Canadienne des Radiologistes (ACR) au Westin Montréal. Le thème de cette année — 𝘝𝘰𝘪𝘳 𝘤𝘦 𝘲𝘶𝘪 𝘤𝘰𝘮𝘱𝘵𝘦 : 𝘧𝘢𝘪𝘳𝘦 𝘱𝘳𝘰𝘨𝘳𝘦𝘴𝘴𝘦𝘳 𝘭𝘢 𝘳𝘢𝘥𝘪𝘰𝘭𝘰𝘨𝘪𝘦 𝘤𝘢𝘯𝘢𝘥𝘪𝘦𝘯𝘯𝘦 — reflète pleinement la mission de Quibim : améliorer le dépistage du cancer grâce à des biomarqueurs d’imagerie basés sur l’IA, et faire évoluer un écosystème de la prostate entièrement connecté, de l’acquisition à l’interprétation. Venez nous rencontrer au stand n°12 pour découvrir les prochaines avancées de la radiologie. #CARASM #Radiology #AIinHealthcare #MedicalImaging
We’re excited to partner with deepc to bring QP-Prostate® to the deepcOS® platform. Together, we’re advancing AI-driven prostate imaging to improve diagnostic confidence and support better patient outcomes. #AIinHealthcare #MedicalImaging #AI
🇮🇹 The Associazione Urologi Italiani AURO.it Congress in Genova brings together the Italian urology community to discuss the latest advances shaping the future of this specialty. Visit Fabio Maggioni and Andrea Lorenzo Polo to discover how solutions like QP-Prostate help optimize prostate MRI analysis by reducing inter-reader variability, increasing confidence levels, and supporting more accurate targeting in fusion biopsy procedures. We’d love to connect and exchange views on the future of imaging techniques in urology! #Urology #AIinHealthcare #MedicalImaging
Quibim’s AI-powered imaging biomarkers are already helping pharmaceutical companies predict treatment response, optimize clinical trial selection, stratify risk, and accelerate drug development. With Itta MacNevin joining as Chief Business Officer, we’re ready to go even further. Strengthening our leadership in life sciences marks a key step as we expand our capabilities and support partners in delivering faster, more precise, and more efficient therapies across oncology, immunology, and neurology. Welcome, Itta! https://bit.ly/3OsR0FV #LifeSciences #Innovation #Oncology #Immunology #Neurology
Improving oncology endpoints with AI requires more than just innovation: it demands coordination, robust evidence, and genuine collaboration. 📄 In a recently published white paper, we have joined forces with Friends of Cancer Research, as part of the ai.RECIST initiative, to explore the limitations of current standards and the opportunities AI offers to redefine response assessment. As part of this initiative, our technology—designed to detect, quantify, and automatically track lesions over time—will be evaluated in an upcoming study, with the goal of enabling more precise, consistent, and scalable approaches. #AIinHealthcare #MedicalImaging #ClinicalTrials #CancerResearch #LifeSciences
Today is #WorldHealthDay, and it’s time to face an uncomfortable truth: we’re still too late. Half of all cancers are detected at stages 3 or 4. Autoimmune diseases take, on average, between 5 and 7 years to be diagnosed. And what is the cost of waiting? A 250% to 400% increase due to late detection. Today’s medicine reacts. Tomorrow’s medicine anticipates. At Quibim, we are shifting from precision medicine to precision health, where AI is shaping a future where diseases will be detected before they even exist. Joel Stutz #AIinHealthcare #MedicalImaging #DigitalTwin
The future of radiology is being shaped right now at The British Institute of Radiology Congress. Maria Proud , MHA, Francesca Evans, David Eggleton and Emmanuel L. took this opportunity to connect with the radiology community and demonstrate how AI-based imaging biomarkers are helping to optimize workflows, increase diagnostic reliability, and ultimately improve patient outcomes. 📩 Couldn't meet them? Book a demo here: https://bit.ly/3Q3mkeF #BIRAI2026 #AIinHealthcare #Radiology #MedicalImaging
🇩🇪 We are in Potsdam, Germany, for the final consortium meeting of the European FLUTE Project - AI & Prostate Cancer. This event marks the culmination of three years of progress in applying AI to healthcare. FLUTE has brought together leading partners to leverage federated learning and develop high-impact, privacy-preserving AI that improves the detection of clinically significant #ProstateCancer. At Quibim, we have contributed by extracting quantitative imaging biomarkers from prostate MRI scans at three hospitals by using QP-Prostate®. These biomarkers have fed into the AI models developed by Gradiant. We have also partnered with the UPC to generate and validate synthetic prostate images. We are proud to be part of this journey and the impact that will follow. #AIinHealthcare #Radiology #MedicalImaging #Radiomics
